Navigation Links
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients

Final Results from Exploratory Phase IIa Clinical Trial in Type 2 Diabetes Patients Announced

TORONTO, June 28, 2007 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition") , today announces the results from its exploratory Phase IIa clinical trial indicating that 4-weeks of daily treatments with gastrin-based therapy, E1-I.N.T.(TM), showed sustained reductions in blood glucose control parameters, including haemoglobinA1C (HbA1c), for 6 months post-treatment. The type 2 diabetes patients enrolled in this study were using metformin with/without thiazolidinediones (TZD). Transition will host a conference call to discuss these data at 5:00 pm EST on Thursday June 28th, 2007.

"These data are very encouraging and show the potential of a regenerative therapy in diabetes," said Sherwyn Schwartz, MD, a noted diabetes researcher and the Director of the Diabetes & Glandular Disease Research Associates in San Antonio, Texas who was the lead investigator of the study.

"Achieving sustained improvements in glucose control for many months post-treatment following a 4-week therapy is unprecedented in type 2 diabetes. The improvements in HbA1c correlated with changes in multiple other clinical parameters suggesting that gastrin-based therapies, and specifically E1-I.N.T.(TM), have the potential to re-engage the body's natural mechanism to regulate glucose," said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition. "The immediate goal is to optimize the dosing regimen in a larger phase II study".

Key Efficacy Findings:

As in Transition's press release on March 5th, 2007, analysis of efficacy parameters was performed on type 2 diabetes patients with HbA1c levels of equal to or greater than 7% prior to treatment.

In the E1-I.N.T.(TM) treated group of patients, the mean HbA1c level was reduced by 0.94% to 1.21% vs. baseline levels in months 2 to 6 post-treatment. Mor
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy

Post Your Comments:
(Date:11/19/2009)...ABBOTT PARK, Ill., Nov. 19 /PRNewswire-FirstCall/ ... ABT ) as one of its Most Admired Corporate Deal... honored Abbott as its Most Admired Dealmaker in ...e of acquisitions and divestitures since January 2...ed its business portfolio with a focus on high-gro...
(Date:11/19/2009)..., Part of International Internet Week of Action ...wswire/ -- The U.S. Food and Drug Administration t...nal effort, called the International Internet Week...s involving medical products. ,, (Logo: http:/..., During the effort, the FDA,s Office of Crimin...
(Date:11/19/2009)... PRINCETON, N.J., Nov. 19 Impliant...atives to traditional spinal fusion surgery, annou...cutive management team as the Vice President of Cl...ttp://www.newscom.com/cgi-bin/prnh/20080527/NETU06...cal and regulatory experience in the spinal and me...
Breaking Medicine Technology:The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 3Study shows cancer vaccines led to long term survival for patients with metastatic melanoma 9391 1Study shows cancer vaccines led to long term survival for patients with metastatic melanoma 9391 2Valve Repair First in New England Done With Robotic Device 52959 1Valve Repair First in New England Done With Robotic Device 52959 2Valve Repair First in New England Done With Robotic Device 52959 3DST Health Solutions Achieves ISO 9001 3A2008 Certification 52954 1DST Health Solutions Achieves ISO 9001 3A2008 Certification 52954 2
... 2007-AstraZeneca today announced clinical,trial d...etiapine,fumarate sustained release), at the Europ...ta demonstrated that the SEROQUEL®,sustained r...release), administered once daily, significantly i...asured by PANSS) and increased the,time to psychia...
...NESS WIRE)--Mar 20, 2007 - MGI PHARMA, INC.,(NASDA...ncology and,acute care, today announced that a ran... 3 trial of Aquavan(R) (fospropofol,disodium) Inje...copy successfully met its primary endpoint of seda...mong patients who,received an initial bolus dose o...
Other Medicine Technology:Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 2Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 3Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 4MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 2MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 3MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 4MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 5MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy 6
(Date:11/20/2009)...ngtime OB/GYN warns against the new breast cancer ...Services Task Force. These guidelines may be cost-...es. When is it wrong to be safe than sorry? , ...vices Task Force recommendations, published in the... has set off a firestorm in the medical community....
(Date:11/20/2009)... Nov. 20 Missouri state employees ...s will now have the option to choose Mercy Health ...en Missouri Consolidated Health Care Plan (MCHCP) ...uth Central Missouri regions include the following...Dallas, Douglas, Greene, Hickory, Howell, Jasper, ...
(Date:11/20/2009)...NGELES, Nov. 20 California minorit...an Families, The Wall/Las Memorias, Latina Breast ...ogram, and the Real Medicine Foundation today sent...the company to reconsider harmful and discriminato...eld specifically calls for an end to the practice ...
(Date:11/20/2009)...20 Today, iconic denim brand DKN...e launch of a capsule gift giving collection offer...season. This collection is inspired by and design...Thanks and Giving® Program, a holiday fundra...mers to "give thanks for the healthy kids in your ...
(Date:11/20/2009)...ov. 20 The US governmen...ggled to get enough food to eat. This startling s...ts who are rapidly aging into poverty. "Forced re...ivorce mean many have incomes that no longer cover... Older women are particularly vulnerable," said K...
Breaking Medicine News(10 mins):Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 3Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 4Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 2Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 3
...nter, a 443-bed,hospital, announced today that it ...tration services so they will be available over th...ek. The medical center has selected,The Beryl Comp... This new relationship will enable local residents...
...focus on preventing attacks , MONDAY, Nov. 12 (Hea...ttacks are the focus of new national asthma guidel...d Blood Institute,s National Asthma Education and ...hey follow these latest guidelines to keep their a...
...le(R),( http://www.spacapsule.com ), the most adva...l techniques combined in one sleek, space-age,mach... PR firms, TransMedia,Group, to publicize the quic...e you from planet stress to planet tranquil," said...
...on exchange (HIE),organizations with public-privat...tant and logical organizational unit for advancing...ttp://www.staterhio.org/conference/documents/conse...mation Management,Association (AHIMA), under contr...
...chlafender Hase GmbH,today released the newest ver...The Text Verification Tool is a patent-protected W...text in print layout ("artwork") on the data,level...orrections. The program thus ensures that only ap...
...re-FirstCall/ - YM BioSciences Inc.,(AMEX: YMI , T...ies, develops,and commercializes differentiated pr...ational and financial results for the first quarte...drug, nimotuzumab," said David Allan,Chairman and ...
Other Medicine News:Health News:Hurley Medical Center Enhances Customer Service Capabilities With Beryl Partnership 2Health News:Experts Release New Asthma Care Guidelines 2Health News:Experts Release New Asthma Care Guidelines 3Health News:The Ultimate Stress Reliever, SpaCapsule(R), the Capsule that Takes You on a Rejuvenating Journey to the Spa, Retains TransMedia Group for Soothing PR 2Health News:Health Information Exchange Consensus Conference Reinforces Key Role of State-Level Entities 2Health News:Health Information Exchange Consensus Conference Reinforces Key Role of State-Level Entities 3Health News:Schlafender Hase Releases Text Verification Tool 4.0 2Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 2Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 3Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 4Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 5Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 6Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 7Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 8Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 9Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 10Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 11Health News:YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS 12
Macroplastique Implantation System
...The Alpha I continues to be a proven, reliable pen...ve mechanical reliability rates of over 97.5% at f...contributes to excellent mechanical reliability ra...des maximum, controlled girth expansion to fill th...
Alpine Reusable Leg Bag - 26 oz. Capacity
Alpine Reusable Leg Bag - 15 oz. Capacity
Medicine Products: